Option Care Health’s Q1 2026: Revenue Grows, Cash Flows Blink, and the Re-Acceleration Plan Starts Now (OPCH)

The ledger for Option Care Health, Inc. (OPCH) shows a quarter with modest revenue momentum and a brushstroke of margin pressure, wrapped in a 2026 guidance refresh. The company posted GAAP EPS of $0.29, up 3.6% year over year, and adjusted diluted EPS of $0.40, while net revenue rose to $1,350.7 million — up 1.3% from a year ago. In the SEO-friendly terms of the moment, investors will be weighing this against the EPS consensus for the year and parsing the revenue forecast versus prior expectations as they calibrate the stock’s trajectory. The headline: the quarter’s cash flow paint is not entirely dry, with operating cash flow of negative $12.1 million, and a decision to deploy capital toward stock repurchases and balance-sheet flexibility via a larger revolver.

Key metrics at a glance

Net revenue: $1,350.7 million, up 1.3% year over year
GAAP net income: $45.3 million, down 3.0%
GAAP diluted EPS: $0.29, up 3.6%
Adjusted EBITDA: $104.8 million, down 6.3%
Adjusted diluted EPS: $0.40, flat versus Q1 2025
Cash from operations: negative $12.1 million
Share repurchases: $17.5 million in the quarter
Revolver facility: expanded from $400 million to $850 million

Management commentary

“The first quarter reflected a mixed performance for our business, and we are not satisfied with our revenue growth momentum,” said John C. Rademacher, President & CEO. The tone is practical: the team will not pretend the numbers glow in the dark, but there is a plan to re-accelerate growth and sustain long-term value creation. The leadership emphasizes execution and patient care quality, with a pivot toward deeper stakeholder relationships and a stronger foundation to weather near-term headwinds.

Updated full-year 2026 guidance

The company reaffirmed and updated its full-year financial outlook. For 2026, Option Care Health now expects:

Net revenue in the range of $5.675 billion to $5.775 billion
Adjusted diluted EPS of $1.82 to $1.92
Adjusted EBITDA of $480 million to $505 million
Cash flow from operating activities of at least $320 million

The numbers suggest the company is leaning into scale and margin discipline to bridge growth with profitability, even as a softer near-term operating cash flow profile remains a point of focus for investors monitoring the EPS trajectory and the revenue forecast trajectory against Street estimates.

Capital allocation and balance-sheet notes

In a quarter that featured pragmatic financial engineering, Option Care Health used liquidity to buy back stock and bolster liquidity for growth. The company repurchased about $17.5 million of its own shares, while the revolving credit facility was expanded to $850 million from $400 million. The combination signals a management posture that is comfortable with leverage as a strategic lever, while keeping liquidity cushions in place for expansion opportunities or operational contingencies.

Conference call and the horizon

A conference call to discuss results was scheduled for April 30, 2026, with an accompanying live webcast at investors.optioncarehealth.com. A 90-day replay window provides a chance to hear the nuanced management take on margin recovery, payer dynamics, and the pace of volume growth in infusion services across the U.S.

About Option Care Health

Option Care Health is described as the nation’s largest independent provider of home and alternate-site infusion services. With thousands of clinicians and a nationwide footprint, the company positions itself as a scale-enabled operator in a fragmented sector that blends clinical care with logistics. The investor communications emphasize the mission to reimagine the infusion care experience across patients, customers, and team members, with a website for more details.

Investor contact

Nicole Maggio, Senior Vice President, Corporate Controller — investor.relations@optioncare.com

Takeaways for the sector and peers

The Q1 2026 results place Option Care Health in a familiar crosshairs: revenue growth is visible, but margin discipline and cash flow timing remain in focus. The elevated revolver and ongoing stock repurchase reflect a management equipo that believes in the path to scale and self-financing growth, albeit with a near-term cash-flow sting to operate more efficiently. For sector peers, this sets a template: explicit guidance updates tied to a clear operating cash-flow plan, capital allocation that balances shareholder returns with liquidity, and a narrative of long-term value creation rooted in clinical quality and geographic reach. The EPS trajectory—$0.29 GAAP, $0.40 adjusted—will invite comparisons to consensus expectations and to peers’ ability to convert revenue into operating profit, especially as price discipline and payer mix influence profitability. If the quarter’s pace can be sustained, expect the sector to drift toward a more disciplined capex-to-revenue stance and a sharper focus on cash-flow-driven upside, with OPCH’s moves acting as a reference point rather than a competitive outlier.